Biologics in Focus

Bayer is investing heavily in its biologics business in both Germany and the United States

Bayer is investing heavily in its biologics business in both Germany and the United States. At their site in Berkeley, California (photo), a 7,500 square meter, three-story laboratory building is currently being constructed. The new laboratories will focus on quality control for future generations of hemophilia products. Bayer is currently developing two new preparations for the treatment of hemophilia A, the most common form of the blood disease. Colleagues from both Pharmaceuticals and Bayer Technology Services are collaborating closely on the planning and implementation of the project.

Similar work is going on in Leverkusen and Wuppertal, where Bayer will be making total investments of around 500 million euros by 2020 to expand its global capacity for hemophilia products. Bayer Technology Services is acting as principal developer and is also taking care of the technology transfer from Berkeley to Wuppertal. A high-bay warehouse was completed at the site in 2015. In addition to the lab facilities, the new premises will also house production areas and facilities for sterile filling and packaging.

Comment
0 Comments
(*) Required
24
Your opinion? Comment now